Scientists dramatically boost CBD absorption with innovative delivery technology

Development and Characterization of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Fixed-Dose Co-Delivery of Hesperetin and Cannabidiol Prepared by Hot-Melt Extrusion.

AAPS PharmSciTech • • Moderately Relevant
🤖

AI Summary

This study addresses a major challenge in cannabis medicine: making CBD more absorbable when taken by mouth. Researchers used a technique called hot-melt extrusion to create a special formulation that combines CBD with hesperetin (a compound from citrus plants) by mixing them with polymers and phospholipids. The result was remarkable—they achieved a 66,369-fold increase in CBD solubility, raising it from barely dissolving in water to 4.314 mg/mL, while simultaneously improving hesperetin's solubility by 987 times. This breakthrough means the body can actually absorb the CBD that patients take, rather than losing it to poor dissolution.

The researchers used sophisticated design-of-experiments methodology to optimize the formulation, finding that the amount of active compounds and the phospholipid content were the critical factors for success. They confirmed the formulations created truly amorphous (non-crystalline) structures, which is key to keeping the compounds dissolved rather than reverting to their natural crystalline state. Testing showed the optimized formulation (F7) not only dissolved exceptionally well but also demonstrated superior permeability across intestinal barriers in laboratory models, suggesting it would be absorbed more effectively in real-world use.

This work is significant beyond just CBD—it demonstrates a powerful delivery platform for any poorly soluble plant-based medicines. For cannabis patients, this means potential improvements in the bioavailability of oral CBD products, potentially allowing lower doses to be more effective and providing more consistent therapeutic benefits. The technique could also be applied to other cannabinoids and plant compounds with similar solubility challenges.

📄 Original Abstract

Hesperetin and cannabidiol (CBD) are promising plant-derived bioactives whose oral performance is limited by poor aqueous solubility. To address the shared biopharmaceutical limitations of both compounds, amorphous PVP K30-phosphatidylcholine dispersions were prepared via hot-melt extrusion (HME). A Box-Behnken design (DoE) was applied to investigate the impact of (i) total API load (hesperetin:CBD mass ratio 1:1), (ii) phospholipid content in the carrier, and (iii) extrusion temperature on the solubility of both actives. The resulting extrudates were characterized by XRPD, DSC, and FT-IR/ATR. Solubility and dissolution profiles were evaluated in phosphate buffer (pH 6.8). In vitro passive permeability was assessed using PAMPA GIT model. DoE indicated that API load and phospholipid content were statistically significant factors for solubility of both hesperetin and CBD, whereas extrusion temperature was not significant within the studied range. XRPD confirmed amorphization for all formulations except F6, which contained a minor residual crystalline fraction of hesperetin. DSC revealed single glass-transition events, supporting good miscibility. The best-performing formulation (F7; 15% APIs, 20% phospholipid, 165°C) achieved solubilities of 4.934 mg/mL (hesperetin; 987-fold increase) and 4.314 mg/mL (CBD; 66,369-fold increase) and showed the highest permeability in PAMPA GIT model. HME-produced PVP K30-phosphatidylcholine amorphous dispersions substantially improved the solubility, dissolution behavior, and in vitro permeability of hesperetin and CBD, highlighting polymer-phospholipid amorphous dispersions as a promising solubility-enhancing platform for delivery of poorly soluble.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.